SCHEMBL3866288

SCHEMBL3866288

Nc1nc(-c2ccccc2)c(-c2ccccc2)nc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 3/20 0.59
KDM4E B2RXH2 3/20 0.50
LMNA P02545 1/20 0.50
NR4A2 P43354 1/20 0.47
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.46
ADORA2A P29274 5/20 0.46
ADORA1 P30542 1/20 0.46
MAPT P10636 1/20 0.45
CSNK1A1 P48729 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
ACMSD Q8TDX5 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP1A2 P05177 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21722434 0.87 ADORA2A (0.56) PLAUADORA2AADORA1
SCHEMBL3864268 0.86 PLAU (0.54) PLAUKDM4ELMNANR4A2ALDH1A1
SCHEMBL11374767 0.86 PLAU (0.54) PLAUKDM4ELMNANR4A2ALDH1A1
SCHEMBL10372796 0.86 ALDH1A1 (0.60) PLAUKDM4ELMNANR4A2ALDH1A1
SCHEMBL4583299 0.84 ATR (0.47) PLAUKDM4ELMNAALDH1A1RAB9A
SCHEMBL27783390 0.82 KDM4E (0.55) PLAUKDM4ELMNANR4A2ALDH1A1
SCHEMBL4584433 0.82 ADORA2A (0.56) PLAUADORA2AADORA1
SCHEMBL20658482 0.82 ADORA2A (0.68) NPC1RAB9AADORA2AADORA1
SCHEMBL4584817 0.80 ADORA2A (0.51) PLAUADORA2AADORA1
SCHEMBL5152965 0.80 ADORA2A (0.47) PLAUALDH1A1HPGDADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1715867-A4 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2009-04-15 EP disclosed
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-06-28 US disclosed
CN-1933838-A Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2007-03-21 CN disclosed
EP-1715867-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-11-02 EP disclosed
WO-2005079802-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GABRA5 PLAU 4847/4885KDM4E 789/4885LMNA 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.